Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MICA-129Met/Val as a therapeutic compass in idiopathic pulmonary fibrosis: prognosis and antifibrotic benefit.

Frontiers in immunology - 1 Jan 2026

Mocci Stefano, Mereu Caterina, Littera Roberto, Deidda Silvia, Cannas Federica, Lorrai Michela, Zedda Elena, Murgia Michela, Sanna Celeste, Giuressi Erika, Lai Sara, Perra Andrea, Floris Matteo, Giglio Sabrina

Abstract excerpt

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by aberrant wound healing, immune dysregulation, heterogeneous trajectories, and poor prognosis. Only two antifibrotic agents, nintedanib and pirfenidone, are currently approved to slow disease progression, yet inter-individual variability in treatment benefit remains largely unexplained. In IPF, impaired...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Histocompatibility Antigens Class I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Idiopathic Pulmonary Fibrosis

Share to Indoles

Share to Killer Cells, Natural

Share to Prognosis

Share to Pyridones

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 42548496
DOI: 10.3389/fimmu.2026.1722213
PMCID: PMC13429406

Genes

MICA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MICA-129Met/Val as a therapeutic compass in idiopathic pulmonary fibrosis: prognosis and antifibrotic benefit.PMID 42548496Read ↗

Recent advances in understanding idiopathic pulmonary fibrosisSemantic proximity Read ↗

DSP rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study.Semantic proximity Read ↗

A new perspective on idiopathic pulmonary fibrosis research: From multi-dimensional mechanistic exploration to advances in precision therapy.Semantic proximity Read ↗

Immunological mechanisms and therapeutic approaches in pulmonary fibrosis.Semantic proximity Read ↗

Idiopathic pulmonary fibrosis and the role of genetics in the era of precision medicineSemantic proximity Read ↗

Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies.Semantic proximity Read ↗

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.Semantic proximity Read ↗

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis.Semantic proximity Read ↗

Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into ImmunopathogenesisSemantic proximity Read ↗

Risk and Association of Specific HLA Alleles With Nintedanib-Induced Gastrointestinal Adverse Reactions: A Discovery Study in an Italian Population.Semantic proximity Read ↗

PCSK6 and Survival in Idiopathic Pulmonary FibrosisSemantic proximity Read ↗

PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.